Pharmaceutical Technology® Group spoke with Erik Wiklund, CEO of Circio, about the future of M&A in the bio/pharmaceutical industry and the struggle small biotech companies face raising funds.

Biotech entrepreneur Sam Waksal has been accused of "reckless conduct," including using a veterinary medicine on a severely ...

The Dow Jones Industrial Average clung to gains in the final hours of trading Tuesday, as the major stock indexes erased much ...

FUJIFILM Diosynth Biotechnologies, a global contract development and manufacturing organization (CDMO) with major operations ...

Eli Lilly gains analyst support after Phase 3 success. Bullish forecasts for obesity dominance and key earnings are set for ...

At least three biotech companies say they’ve received orders to stop their work related to a Biden administration initiative ...

Beth Marsh will lead commercialization for Neurotech, which gained FDA approval for its eye disease therapy. Neurotech in May ...

Biotech giant Regeneron Pharmaceuticals, Inc. REGN is slated to report first-quarter 2025 results on April 29, 2025. The ...

Paul Stoffels left his perch as J&J’s chief scientific officer in 2022 to replace Galapagos’ founding CEO Onno van de Stolpe, ...

BD is rolling out a new monitoring platform equipped with artificial intelligence-powered programs that aim to predict ...

Regeneron signs $3 billion deal with FUJIFILM to expand biologics manufacturing in North Carolina, boosting U.S. capacity and ...

The biotech mergers and acquisitions market faces significant headwinds in the first half of 2025. These challenges include frozen capital ...